Purpose Radiotherapy-related dermatological toxicities over time have not been well quantified. We examined during and immediately following radiation therapy skin toxicities over time in a randomized study of mometasone furoate vs placebo during breast radiotherapy. Material and methods Patients with breast cancer undergoing radiotherapy to the breast or chest wall were randomized. Symptoms related to skin toxicity were addressed weekly using provider-reported Common Terminology Criteria for Adverse Events (CTCAE v3.0) and 4 patient-reported outcomes (PRO) surveys. We applied repeated measures and risk analysis methodologies. Results One hundred seventy-six patients were enrolled. By CTCAE, significant differences favoring mometasone were detected over time in all toxicities except skin striae, atrophy, and infection. Statistically significant differences between arms at baseline but not over time occurred for all Linear Analog Self-Assessment. Statistically significant differences occurred for all symptoms in the temporal profile of symptoms as measured by PRO surveys (all P < .001).
Conclusions The use of longitudinal methods enhanced the ability of PRO tools to detect differences between study arms. Our results strengthened the conclusions of the original report that mometasone reduced acute skin toxicities. PRO surveys can accurately assess patients' experiences of symptom type and intensity over time and should be included in future clinical trials. Summary For radiotherapy-related dermatological toxicity, we hypothesized that clinically significant differences over time, if any, can be found by repeated measures. We examined the acute skin toxicities in a randomized study of mometasone vs placebo during breast radiotherapy. For secondary end points, we showed that longitudinal methods enhanced the detection of differences between study arms and strengthened the conclusions from the original report. Frequent patient-reported outcome surveys over time should be included in future clinical trials. 
Introduction
Radiation-induced dermatitis is the most common side effect of whole breast or chest wall radiotherapy (RT) [1] [2] [3] . Its symptoms are associated with decreased quality-of-life (QOL) [4] and increased expenses [5] . The original report of the North Central Cancer Treatment Group's (NCCTG [Alliance for Clinical Trials in Oncology]) phase 3 N06C4 randomized, double-blind, placebo-controlled trial [6] documented the efficacy of mometasone furoate for prevention of radiation dermatitis in breast cancer patients. Although the provider-assessed primary end point showed no difference in the mean maximum grade of radiation dermatitis by treatment arm (1.2 for mometasone vs 1.3 for placebo; P = .18) as measured by the Common Terminology Criteria for Adverse Events (CTCAE v3.0), statistically significant differences favoring mometasone were observed for multiple patient-reported outcomes (PROs) measured by the Skindex-16 (SD16) and the Skin Toxicity Assessment Tool (STAT). Previously, pooled analysis from three studies, including N06C4, favored concomitant use of CTCAE and PRO assessment tools (e.g., SD16) of patients' experiences in clinical trials [7] . A detailed analysis comparing N06C4 provider-assessed CTCAE and PRO measures of acute skin toxicity has also been reported [8] . In these studies, patients' responses were evaluated either at individual time points, changes from baseline, or as binary incidence rates for symptoms or toxicity. The evolution of CTCAE-assessed RT-related dermatological symptoms over time and their relationship to PROs have not been studied.
Breast symptoms increase during the course of RT but improve post-treatment [9] . Thus, determining an accurate temporal relationship is important in radiation-related symptom-control trials. This study reports the results of two secondary goals of N06C4 (1) to examine the temporal profile of PROs in determining the effect of mometasone cream on the evolution and spectrum of acute skin toxicity and symptoms and (2) to explore relationships via correlations between CTCAE and PRO results.
Methods and materials Patient and assessment tool selections
The N06C4 study was approved by the institutional review boards of participating hospitals. Written informed consent was obtained. Breast cancer patients (N = 176, including ductal carcinoma in situ) undergoing external beam RT to the breast or chest wall were randomized using the Pocock-Simon dynamic randomization procedure to receive topical 0.1 % mometasone or an identical-appearing placebo cream daily. Randomization stratification factors were field type, regional lymph node treatment, and cumulative RT dose. Patients began mometasone or placebo use prior to the third RT fraction and continued during RT. RT was administrated daily via regularly fractionated regimens (1.75-2.12 Gy per fraction). Symptoms and PRO assessments were assessed at baseline and weekly during RT.
The CONSORT (Consolidated Standards of Reporting Trials) diagram is presented in Fig. 1 . One hundred sixtyfive patients (98 %) received 5 weeks of RT totaling 50 Gy, after which 151 (89 %) received 6 weeks, 109 (64 %) received 7 weeks, and 18 (11 %) received 8 weeks. Those that had ≥6 weeks of treatment had a boost applied. Only two patients received RT at 9 weeks; thus, this time point was excluded from analysis to prevent any potential bias. Most patients (n = 136, 77 %) completed the study per protocol. Missing data were minimal (29/1286 weeks [2 %] of collected PRO assessments). Two patients account for 13 of the 29 weeks of missing data.
Four assessment tools recorded PROs: SD16 [10] , STAT [11] , Symptom Experience Diary (SED), and Linear Analog Self-Assessment (LASA) [12] (Table 1 ). Each assessment tool measured different spectrums of symptoms and perceptions of toxicities. QOL assessments were scored using PRO-specific scoring algorithms and converted to percentages (0 to 100, with 100 being the best QOL or least severity of reported symptoms), to allow for direct comparison of assessment scores with differing ranges. For the SED tool, five subscales were created by grouping similar symptom characteristics (e.g., peeling includes wet and dry peelings perceived by patients), and scores were averaged accordingly. For STAT, only the PRO items [13] were included in this analysis.
The CTCAE version 3.0 [14] was used for grading provider-assessed skin toxicities. Grading scale values ranged from 0 (no adverse events [AEs]) to 5 (death). Specific grade determination criteria for radiation-induced dermatitis are Bgrade 1, faint erythema or dry desquamation; grade 2, moderate erythema and edema, moist desquamation confined to skin folds and creases; grade 3, moist desquamation other than skin folds and creases, or bleeding induced by minor trauma or abrasion; grade 4, ulceration of full thickness dermis, spontaneous bleeding from involved site^ [15] . Other skin AEs evaluated using the CTCAE criteria were pruritus, burn, striae, hypopigmentation, atrophy, infection, and skin disorders (skin and subcutaneous tissue disorders). A new AE category was compiled for this study and called Bdermatitis-related symptoms,^which was assigned a grade being the maximum grade of any of the eight individual AEs per patient each week (Table 1) .
Repeated measures
All repeated measures analyses were conducted using SAS version 9.3 (SAS Institute Inc). Repeated measures analyses [16, 17] have been widely used in prospective randomized trials using repeated evaluations over time for end points such as toxicity [18] and treatment response [19] in head and neck cancer, QOL in prostate cancer [20, 21] , surgical outcomes in prospective lung [22] and breast [23] cancer trials, and pain control for cancer patients [24] .
PRO response variables and AE grades were modeled using study arm and week of treatment as classification variables with interaction effects. The repeated measures analysis utilized the growth curve option to allow the testing of individual differences in patterns of responses over time. A statistically significant intercept would indicate a difference between arms at baseline and a statistically significant difference in slopes would indicate a favorable arm of treatment over time. Type 3 F test P values were reported. Independent variables (age, sex, race, stratification factors, smoking status, and use of chemotherapy) were excluded as covariates since they were balanced between treatment arms. Effect sizes were computed for PRO scores as the difference between group means divided by pooled SD. Sizes of 0.2, 0.5, and 0.8 were interpreted as small, medium, and large [25] .
Pearson correlation
Pearson correlation coefficients were estimated between the PRO tools and between provider-assessed AEs and the PRO tools, regardless of time point.
Risk analysis
Risk analysis was performed to calculate the logistic odds ratios (ORs) for the incidence of dermatitis-related AEs assessed by treatment arm and over time. All eight AEs mentioned previously and the dermatitis-related symptom variables were modeled.
Results

CTCAE outcome
One hundred sixty-nine patients (96 %) were evaluable for toxicity. During fractionated external beam RT, providerobserved symptoms typically started during weeks 3 and 4, peaked between weeks 4 and 7, and subsided after weeks 8 and 9. For evaluable patients each week, the grade 2+ AE rates (previously reported [6] ) were 16 % (26/167 patients), week 4; 28 % (47/165 patients), week 5; 38 % (58/151 patients), week 6; 36 % (39/109 patients), week 7; and 22 % (4/18 patients), week 8. For dermatitis-related symptoms, 20 % (110/537 events) were grade 2 or higher for mometasone vs 18 % (124/688 events) for placebo; 1 % (n = 7) and 2 % (n = 16) of grade 3 toxicities were reported for mometasone and placebo, respectively. Similar trends were observed for radiationinduced dermatitis, with event frequency about half that for dermatitis-related symptoms.
Strict comparison of mean values of physician-assessed CTCAE grades, regardless of weeks, revealed no obvious trend by study arm for any of the associated AEs (Table 2) . However, some differences were detected when the repeated measures growth curve analyses were applied. At baseline, patients in the placebo arm had a slightly higher average grade in dermatitis-related symptoms (mean, 0.14 vs 0.06; P = .03), skin striae (mean, 0.07 vs 0.01; P = .003), and skin atrophy (mean, 0.01 vs 0; P = .02). Differences over time were highly statistically significant for radiation-induced dermatitis, dermatitis-related symptoms, pruritus, burning, and skin disorders including skin and subcutaneous tissue disorders (all P < .001). In all of these associations, after cycle 1, the placebo arm showed higher grades of AEs. Hypopigmentation (P = .02) was also statistically significantly different over time, for which the placebo group showed higher grades of toxicities between weeks 3 and 6.
Patient-reported outcomes
Similar to the temporal trends of CTCAE, symptoms as measured by PRO scores typically were lowest by week 4 to week 5 but recovered quickly toward and immediately after treatment ended. LASA scores were typically constant over time. All mean assessment scores were above 70 points for both arms (Table 3 ). In 84 % (16/19) of subscales, mometasone was consistently higher than placebo by 1 to 5 absolute points (100-point scale), which amounted to significant differences between arms for all SD16 scores (all P ≤ .01), for LASA mental, physical, emotional, and spiritual well-being (all P ≤ .03), for STAT burning, itching, and pulling (all P ≤ .02), and for SED fatigue and erythema (all P ≤ .002) when time was not taken into consideration.
Repeated measures growth curve analyses indicated some significant differences at baseline (intercept P value) for LASA measures and SED fatigue. In all cases, the mometasone arm had higher scores indicating better QOL and less fatigue. All temporal profiles of SD16 and STAT responses were significantly different between arms, favoring mometasone. SED scores of swelling, appearance, and peeling were significant over time (P value =.001) but it was not possible to detect a superior arm. In regard to LASA, there were no statistically significant differences over time between mometasone and placebo, even though graphically and qualitatively it may appear that the mometasone scores were slightly higher (Supplementary Figure e1) .
Because potential bias of including weeks 7 and 8 in the analysis may exist since so few patients were receiving treatment, in two separate analyses, the repeated measures were applied to data collected during weeks 1 through 6 only, and also to data collected during weeks 1 through 7 only. Similar results were obtained for the analysis using 8 weeks of data.
Effect sizes were calculated as planned, and the overall differences between arms were estimated and were generally small (range, 0.08-0.3). For individual weeks, some effect 
CTCAE and PRO correlations
Previously, the correlative relationship among CTCAE and PRO-based SD16 and STAT individual items (not subscales) has been reported [8] ; SED and LASA items were not included. In this expanded PRO-to-PRO comparative analysis for all surveyed PRO tools, including SED and LASA, the 4 SD16 subscales were highly correlated. The 6 LASA items were also highly correlated (all r > 0.72; all P < .01). The SD16 total and subscales, compared to SED subscales, were consistent and intercorrelated. Some correlations of SD16 with STAT subscales were moderate. The STAT and SED survey tools had mostly mild correlations within their own subscales; intercorrelations between their subscales were similarly mild. CTCAE grades correlated with a limited number of PRO subscales. Only 3 % (5/171) of correlations were moderate (n = 4) or strong (n = 1). Moderate correlations were dermatitis-related symptoms with SD16 symptom (r = −0.53), STAT itching (r = −0.54), SED erythema (r = −0.55), and pruritus with SD16 symptom (r = −0.55); the only strong correlation was between pruritus and STAT itching (r = −0.74).
Temporal risk analyses of AE development
The forest plot of ORs for incidence of select dermatitisrelated AEs (including radiation-induced dermatitis) by arm and week generally favored mometasone (Fig. 2) [6] and also the repeated measures analyses in this study.
Discussion
To our knowledge, this is the first repeated measures analysis to prospectively evaluate dermatitis-related symptoms in breast cancer patients receiving external beam RT. No differences were found by repeated measures analyses in physicianassessed AE values as measured between arms alone, which were consistent with findings from the original trial [6] . However, statistically significant differences were found temporally for many of the AEs. Differences were seen in multiple PRO measures that assessed specific symptoms, suggesting that PROs may be just as appropriate as provider-reported assessments in evaluating day-to-day AEs and symptoms that temporally evolve with treatment. The inclusion of temporal Abbreviation: CTCAE Common Terminology Criteria for Adverse Events a Significance was defined as P < .05
and longitudinal statistical methods enhanced the ability of PRO tools to detect differences between arms in the prospective N06C4 trial. Patients with breast cancer experience various symptoms and decreased functional status while undergoing RT. However, while qualitatively well recognized [26] , QOL studies are lacking on radiation-induced dermatitis and other skin symptoms in breast cancer patients [27] . Recently completed prospective trials evaluating QOL [4] and topical applications for alleviation of dermatitis symptoms [28, 29] did not use repeated measures analyses, instead reporting a detailed, generalized model for analyzing long-term repeated measures data [4] . The potential application of repeated measures analyses in dermatitis-related symptom control trials of breast and head and neck cancers is emerging.
Forty percent of patients may experience more than one symptom concurrently [30] , which further emphasizes the value of temporally focused repeated measures evaluations by provider-assessed surveys and/or PROs. Generalized PROs (not breast cancer-specific) have been piloted for association with provider-assessed dermatitis symptoms, but results were not statistically significant [2] . In the original N06C4 trial [6] , the only statistically significant CTCAE toxicity was pruritus (P = .04), which was not the primary end point. However, besides symptoms directly related to dermatitis (Table 1) , other domains of symptoms and toxicity in breast cancer patients can also be temporally affected as therapy continues: the more subtle yet important differences in QOL may only be detectable with PROs. In the same trial [6] , PRO evaluations showed several items in SD16 (itching, irritation, symptom persistence or recurrence, annoyance with skin problems) and STAT (itching, burning sensation) to differ by arm, all favoring mometasone. No other measures, by CTCAE or PRO, favored placebo. Similar results were also observed in our study with repeated measures analyses.
The PRO-to-PRO intracorrelations and intercorrelations among survey tools showed SD16 and LASA to have better reliability and self-correlation for RT-related symptom control trials; SD16 also demonstrated good intercorrelation with STAT and SED survey tools. Similar to a previous report [8] , this analysis suggested that PRO tools may be a stronger indication of patients' subjective experiences and symptom reporting during and immediately after RT treatments. Our current analysis expanded upon the findings of NebenWittich et al. [8] by incorporating the remaining 2 PRO survey tools (LASA and SED). As PRO appeared to capture a wide range of symptoms and side effects unnoticed by providerassessed survey tools, our results showed that CTCAE and PRO demonstrated little intercorrelation. This finding was similar to those of other studies in breast [2, 8, 14, 24] and other [18, 21, 31] cancers. Further research into the reason for this is required. Abbreviations: LASA Linear Analog Self-Assessment, SD16 Skindex-16, SED Symptom Experience Diary, STAT Skin Toxicity Assessment Tool a Modeling reported in Table 3 included weeks 1 through 8 For RT-related dermatitis, topical corticosteroid creams have been tried with some success [13, 32] . Our results strengthened the conclusion from the original report that compared to placebo; mometasone reduced acute skin toxicities and symptoms at a potentially clinically significant level. As shown by our data, frequent PROs may provide a good assessment of patients' experiences of varying symptoms and intensity of AEs as treatment progresses. Other studies have also shown that PRO tools more accurately reflect patients' symptoms and experience compared to provider-based assessments such as CTCAE [8, 33] . Provider-assessed outcomes and PROs may indeed complement each other as the next generation of AE scales [34] . PRO tools should be adapted for prospective symptom control studies in radiation dermatitis research and may also be introduced into clinical practice for measuring and temporally evaluating symptoms of patients during and after RT treatment.
By effect size analyses, several PRO items demonstrated potential clinical significance, favoring mometasone by having moderate benefits for individual time points at 4, 5, and 6 weeks, which agreed well clinically, as physicians and patients typically, observe most RT-related dermatitis 4 to 6 weeks after starting radiation therapy.
Currently, the use of mometasone furoate has not been adapted as the standard of care for RT-related dermatitis in breast cancer patients; although several PRO and CTCAE temporal end points were statistically significantly different in this study, the clinically relevant magnitude of these differences remains to be validated. Several PRO items demonstrated small to moderate and statistically significant difference by arm over time by repeated measures and effect size analyses, but the clinical significance of these differences requires further testing in future prospective trials.
Patient breast size was not taking into account in the stratification of patients in this study. Hindley et al. did incorporate bra cup size into a study and have stated that they will be analyzing the effect of breast size in the future [35] . Also, the late effects of mometasone on breast cancer patients have not been documented yet and require further research. Standardized breast photography (SBP) could be a potential future methodology useful for visualizing the effect of mometasone; such methods have been used in other specialties to examine the effects of treatments on cosmesis [36] .
Conclusion
End points such as patients' subjective symptom spectrum during RT and toxicity experience are temporally evolving, dynamic targets. Compared to provider-assessed outcomes, PRO tools captured a wider, more comprehensive range of experiences and symptoms, especially when time variables and trends were considered by statistical techniques such as repeated measures analyses. Fig. 2 Common Terminology Criteria for Adverse Events (CTCAE)-based risk analyses. Forest plot of logistic odds ratios (ORs) for dermatitis-related adverse events (including radiation-induced dermatitis) by arms and weeks. P < .05 indicates statistical significance. LCL lower confidence limit, UCL upper confidence limit
